ABECMA

Brand name authorized in: Ireland Poland

Active ingredients

The drug ABECMA contains one active pharmaceutical ingredient (API):

1 Idecabtagene vicleucel
UNII 8PX1X7UG4D - IDECABTAGENE VICLEUCEL

Idecabtagene vicleucel is a chimeric antigen receptor (CAR)-positive T cell therapy targeting B-cell maturation antigen (BCMA), which is expressed on the surface of normal and malignant plasma cells. The CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, a CD3-zeta T cell activation domain, and a 4-1BB costimulatory domain. Antigen-specific activation of idecabtagene vicleucel results in CAR-positive T cell proliferation, cytokine secretion and subsequent cytolytic killing of BCMA-expressing cells.

Read about Idecabtagene vicleucel

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
Summary of Product Characteristics (SPC)

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
PL
Rejestru Produktów Leczniczych
Identifier(s): 100457776